Celldex Therapeutics (CLDX) Enterprise Value (2010 - 2026)

Celldex Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$451.5 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 32.95% year-over-year to -$451.5 million; the TTM figure through Mar 2026 stood at -$451.5 million (up 32.95% YoY), while the FY2025 annual figure was -$518.6 million, up 28.5% from the prior year.
• Enterprise Value for Q1 2026 stood at -$451.5 million, up from -$518.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$235.3 million in Q3 2023, with the low at -$823.8 million in Q1 2024.
• The 5-year median for Enterprise Value is -$451.5 million (2026), against an average of -$501.2 million.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value plunged 221.23% in 2024, then jumped 32.95% in 2026.
• Celldex Therapeutics' Enterprise Value stood at -$305.0 million in 2022, then slumped by 38.91% to -$423.6 million in 2023, then sank by 71.22% to -$725.3 million in 2024, then rose by 28.5% to -$518.6 million in 2025, then gained by 12.94% to -$451.5 million in 2026.
• Business Quant data shows CLDX's Enterprise Value at -$451.5 million in Q1 2026, -$518.6 million in Q4 2025, and -$583.2 million in Q3 2025.